Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products.

We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market. 

Avillion is staffed with a team of expert professionals with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis.

Our offices are in London, United Kingdom, and we are financed by our international investors, Abingworth and Clarus Ventures.